BCAX 8-K: Q3 2025 results and highlights furnished via Exhibit 99.1

Rhea-AI Filing Summary

Bicara Therapeutics (BCAX) furnished an 8-K announcing it issued a press release with financial results and business highlights for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference.

The information under Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act, and therefore is not subject to Section 18 liabilities. BCAX common stock trades on The Nasdaq Global Market.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

FALSE000202365800020236582025-11-102025-11-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): November 10, 2025

___________________________________

Bicara Therapeutics Inc.

(Exact name of registrant as specified in its charter)

___________________________________

Delaware (State or other jurisdiction of incorporation or organization)			001-42271 (Commission File Number)			83-2903745 (I.R.S. Employer Identification Number)
116 Huntington Avenue, Suite 703 Boston, MA 02116
(Address of principal executive offices and zip code)
(617) 468-4219
(Registrant's telephone number, including area code)

___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class			Trading Symbol			Name of each exchange on which registered
Common Stock, $0.0001 par value			BCAX			The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.

Emerging growth company    ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 - Results of Operations and Financial Condition.

On November 10, 2025, Bicara Therapeutics Inc. (the “Company”) issued a press release announcing its financial results and business highlights for the quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 - Financial Statements and Exhibits

(d) The following exhibits are being filed herewith:

Exhibit No.						Description
99.1						Press Release of Bicara Therapeutics Inc. dated November 10, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 10th day of November, 2025.

Bicara Therapeutics Inc.
By:			/s/ Claire Mazumdar
Name:			Claire Mazumdar
Title:			Chief Executive Officer

FAQ

What did Bicara Therapeutics (BCAX) disclose in this 8-K?

The company furnished a press release with financial results and business highlights for the quarter ended September 30, 2025, as Exhibit 99.1.

Which item of the 8-K applies to Bicara Therapeutics (BCAX)?

Item 2.02 – Results of Operations and Financial Condition.

Is the BCAX press release considered filed or furnished?

It is furnished, not filed, and therefore not subject to Section 18 of the Exchange Act.

What period do the disclosed results cover for BCAX?

The quarter ended September 30, 2025.

When was the BCAX press release dated?

November 10, 2025.

Where can investors find the BCAX press release?

It is attached as Exhibit 99.1 to the 8-K.

What is Bicara Therapeutics’ trading symbol and exchange?

BCAX on The Nasdaq Global Market.